Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market
13 Nov
2017
Written by Mike Elliott

Hemispherx $HEB Ramping Up Manufacturing to Pursue Multi-Billion Dollar Immuno-Oncology Market »

In this episode of CEOLIVE we’re joined by Mr. Thomas Equels, CEO of Hemispherx Biopharma, which trades on the NYSE under ticker HEB. Hemispherx is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders.

Read more...
Citius Pharma $CTXR Receives “Fast Track” Designation By FDA For Potential $500M Product – Mino-Lok™
2 Nov
2017
Written by Mike Elliott

Citius Pharma $CTXR Receives “Fast Track” Designation By FDA For Potential $500M Product – Mino-Lok™ »

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of unique therapeutic products in adjunctive cancer care with a focus on infectious diseases.

Read more...

Login

Lost your password?